Mengsha Tong

Prof. Mengsha Tong


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 March 2023 in Briefings in Bioinformatics
Verified
Journal Article
Closed access
PDF file
Mengsha TongMengsha Tong
Mengsha Tong
YLYuxiang Lin
Yuxiang Lin
WYWenxian Yang
Wenxian Yang
JSJinsheng Song
Jinsheng Song
ZZZheyang Zhang
Zheyang Zhang
RYRongshan Yu
Rongshan Yu
Colorectal cancer (CRC) is one of the most common gastrointestinal malignancies. There are few recurrence risk signatures for CRC patients. Single-cell RNA-sequencing (scRNA-seq) provides a high-resolution platform for prognostic signature detection. However, scRNA-seq is not practical in large cohorts due to its high cost and most single-cell experiments lack clinical phenotype information. Few studies have been reported to use external bulk transcriptome with survival time to guide the detection of key cell subtypes in scRNA-seq data. We proposed scRankXMBD, a computational framework to prioritize prognostic-associated cell subpopulations based on within-cell relative expression orderings of gene pairs from single-cell transcriptomes. scRankXMBD achieves higher precision and concordance compared with five existing methods. Moreover, we developed single-cell gene pair signatures to predict recurrence risk for patients individually. Our work facilitates the application of the rank-based method in scRNA-seq data for prognostic biomarker discovery and precision oncology. scRankXMBD is available at https://github.com/xmuyulab/scRank-XMBD. (XMBD:Xiamen Big Data, a biomedical open software initiative in the National Institute for Data Science in Health and Medicine, Xiamen University, China.)

17 June 2024 in Cell Reports Methods
Verified
Journal Article
Open access
JXJiajing Xie
Jiajing Xie
YCYing Chen
Ying Chen
SLShijie Luo
Shijie Luo
WYWenxian Yang
Wenxian Yang
YLYuxiang Lin
Yuxiang Lin
RYRongshan Yu
Rongshan Yu
Cancer of unknown primary (CUP) represents metastatic cancer where the primary site remains unidentified despite standard diagnostic procedures. To determine the tumor origin in such cases, we developed BPformer, a deep learning method integrating the transformer model with prior knowledge of biological pathways. Trained on transcriptomes from 10,410 primary tumors across 32 cancer types, BPformer achieved remarkable accuracy rates of 94%, 92%, and 89% in primary tumors and primary and metastatic sites of metastatic tumors, respectively, surpassing existing methods. Additionally, BPformer was validated in a retrospective study, demonstrating consistency with tumor sites diagnosed through immunohistochemistry and histopathology. Furthermore, BPformer was able to rank pathways based on their contribution to tumor origin identification, which helped to classify oncogenic signaling pathways into those that are highly conservative among different cancers versus those that are highly variable depending on their origins.

10 May 2024 in Computational and Structural Biotechnology Journal
Verified
Journal Article
Open access
JLJiaao Li
Jiaao Li
JTJingyi Tian
Jingyi Tian
YLYachen Liu
Yachen Liu
ZLZan Liu
Zan Liu
Mengsha TongMengsha Tong
Mengsha Tong
Multi-omics technologies, encompassing genomics, proteomics, and transcriptomics, provide profound insights into cancer biology. A fundamental computational approach for analyzing multi-omics data is differential analysis, which identifies molecular distinctions between cancerous and normal tissues. Traditional methods, however, often fail to address the distinct heterogeneity of individual tumors, thereby neglecting crucial patient-specific molecular traits. This shortcoming underscores the necessity for tailored differential analysis algorithms, which focus on particular patient variations. Such approaches offer a more nuanced understanding of cancer biology and are instrumental in pinpointing personalized therapeutic strategies. In this review, we summarize the principles of current individualized techniques. We also review their efficacy in analyzing cancer multi-omics data and discuss their potential applications in clinical practice.

22 November 2024 in Briefings in Bioinformatics
Verified
Journal Article
Open access
ZZZheyang Zhang
Zheyang Zhang
RTRonghan Tang
Ronghan Tang
MZMing Zhu
Ming Zhu
ZZZhijuan Zhu
Zhijuan Zhu
JZJiali Zhu
Jiali Zhu
JHJialiang Huang
Jialiang Huang
Acute myeloid leukemia (AML) demonstrates significant cellular heterogeneity in both leukemic and immune cells, providing valuable insights into clinical outcomes. Here, we constructed an AML single-cell transcriptome atlas and proposed sciNMF workflow to systematically dissect underlying cellular heterogeneity. Notably, sciNMF identified 26 leukemic and immune cell states that linked to clinical variables, mutations, and prognosis. By examining the co-existence patterns among these cell states, we highlighted a unique AML cellular ecosystem (ACE) that signifies aberrant tumor milieu and poor survival, which is confirmed by public RNA-seq cohorts. We further developed the ACE signature (ACEsig), comprising 12 genes, which accurately predicts AML prognosis, and outperforms existing signatures. When applied to cytogenetically normal AML or intensively treated patients, the ACEsig continues to demonstrate strong performance. Our results demonstrate that large-scale systematic characterization of cellular heterogeneity has the potential to enhance our understanding of AML heterogeneity and contribute to more precise risk stratification strategy.

2 April 2022 in Briefings in Bioinformatics
Verified
Journal Article
Closed access
PDF file
YLYachen Liu
Yachen Liu
YLYalan Lin
Yalan Lin
WYWenxian Yang
Wenxian Yang
YLYuxiang Lin
Yuxiang Lin
YWYujuan Wu
Yujuan Wu
RYRongshan Yu
Rongshan Yu
Liquid chromatography–mass spectrometry-based quantitative proteomics can measure the expression of thousands of proteins from biological samples and has been increasingly applied in cancer research. Identifying differentially expressed proteins (DEPs) between tumors and normal controls is commonly used to investigate carcinogenesis mechanisms. While differential expression analysis (DEA) at an individual level is desired to identify patient-specific molecular defects for better patient stratification, most statistical DEP analysis methods only identify deregulated proteins at the population level. To date, robust individualized DEA algorithms have been proposed for ribonucleic acid data, but their performance on proteomics data is underexplored. Herein, we performed a systematic evaluation on five individualized DEA algorithms for proteins on cancer proteomic datasets from seven cancer types. Results show that the within-sample relative expression orderings (REOs) of protein pairs in normal tissues were highly stable, providing the basis for individualized DEA for proteins using REOs. Moreover, individualized DEA algorithms achieve higher precision in detecting sample-specific deregulated proteins than population-level methods. To facilitate the utilization of individualized DEA algorithms in proteomics for prognostic biomarker discovery and personalized medicine, we provide Individualized DEP Analysis IDEPAXMBD (XMBD: Xiamen Big Data, a biomedical open software initiative in the National Institute for Data Science in Health and Medicine, Xiamen University, China.) (https://github.com/xmuyulab/IDEPA-XMBD), which is a user-friendly and open-source Python toolkit that integrates individualized DEA algorithms for DEP-associated deregulation pattern recognition.

23 September 2024 in Briefings in Bioinformatics
Verified
Journal Article
Open access
PDF file
JXJiajing Xie
Jiajing Xie
YSYuhang Song
Yuhang Song
HZHailong Zheng
Hailong Zheng
SLShijie Luo
Shijie Luo
YCYing Chen
Ying Chen
Mengsha TongMengsha Tong
Mengsha Tong
Despite advanced diagnostics, 3%–5% of cases remain classified as cancer of unknown primary (CUP). DNA methylation, an important epigenetic feature, is essential for determining the origin of metastatic tumors. We presented PathMethy, a novel Transformer model integrated with functional categories and crosstalk of pathways, to accurately trace the origin of tumors in CUP samples based on DNA methylation. PathMethy outperformed seven competing methods in F1-score across nine cancer datasets and predicted accurately the molecular subtypes within nine primary tumor types. It not only excelled at tracing the origins of both primary and metastatic tumors but also demonstrated a high degree of agreement with previously diagnosed sites in cases of CUP. PathMethy provided biological insights by highlighting key pathways, functional categories, and their interactions. Using functional categories of pathways, we gained a global understanding of biological processes. For broader access, a user-friendly web server for researchers and clinicians is available at https://cup.pathmethy.com.